There are currently 58 active clinical trials seeking participants for Renal Cell Carcinoma research studies. The states with the highest number of trials for Renal Cell Carcinoma participants are California, Texas, New York and Florida.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT04792463
Recruiting
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screen... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Register for Updates
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
NCT05725421
Recruiting
This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/11/2025
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Renal Cell Carcinoma
Register for Updates
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
NCT03630536
Recruiting
There are limited data regarding the biology and treatment of TFE Renal Cell Carcinoma (TFE RCC). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of TFE RCC. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with TFE RCC, prospectively. Cases are identified through: 1. Existing clinical and/or cancer... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/17/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Renal Cell Carcinoma
Register for Updates
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
NCT05319015
Recruiting
This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024
Recruiting
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2025
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Register for Updates
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926
Recruiting
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/18/2025
Locations: UCSF Medical Center at Mission Bay ( Site 5008), San Francisco, California +5 locations
Conditions: Renal Cell Carcinoma
Register for Updates
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444
Recruiting
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +56 locations
Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Register for Updates
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
NCT06005818
Recruiting
The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease. The main question\[s\] it aims to answer are: * what is the progression free survival of a cohort of high risk resected RCC patients when treated based on MRD * what is the overall survival of high risk resected RCC patients when treated based on MRD Participants will forgo adjuvant therapy with pembrolizumab i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Renal Cell Carcinoma
Register for Updates
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
NCT00001238
Recruiting
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Clear Cell Renal Cancer, Familial Renal Cancer (FRC)
Register for Updates
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
NCT05098132
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Arizona Cancer Center, Tucson, Arizona +26 locations
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency, Untreated Advanced NSCLC, 1st Line NSCLC
Register for Updates
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
NCT05721222
Recruiting
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers. Participants will have cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable) or relapsed or refractory to prior treatments. This Phase 1/2 study will have three parts. The dose escalation part of the study will find out how much and how frequently GEN1160... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: City of Hope Comprehensive Cancer Center - Duarte, Duarte, California +16 locations
Conditions: Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793
Recruiting
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +8 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Register for Updates